We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia.
- Authors
Serpa, Mariana; Sanabani, Sabri S.; Dorlhiac-Llacer, Pedro Enrique; Nardinelli, Luciana; de Barros Ferreira, Patricia; Borges Martins, Thays Fernanda; Seguro, Fernanda; Bendit, Israel
- Abstract
Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time of the suboptimal response in patient 1 and the failure in patient 2, we were able to detect the F359I mutation in the BCR-ABL tyrosine kinase domain using DNA sequencing in both patients. Therefore, it was decided to change the therapeutic regimen to dasatinib at a dose of 100 mg once daily in both patients. This change resulted in the achievement of complete cytogenetic remission in patient 1 after 4 months and a major molecular response within 2 and 3 months in both patients. Detection of the F359I mutation in our two cases likely explains the suboptimal response to imatinib in case 1 and the failure in case 2. This implies that in such cases dasatinib should be considered to effectively suppress the mutated clones. Copyright © 2011 S. Karger AG, Basel
- Subjects
CASE studies; IMATINIB; TREATMENT of chronic myeloid leukemia; MYELOID leukemia; LEUKEMIA treatment; PROTEIN-tyrosine kinases
- Publication
Acta Haematologica, 2011, Vol 127, Issue 1, p56
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000333092